Cephalon, Inc.

Mark Terence Liddament

Anthony Gerard Doyle

Adam Clarke

Bridget Ann Cooksey

Matthew Pollard

Lynn Dorothy Poulton

Julia Rozenfeld

Anna Mikaela Bracken

Marta Szabat

Anna Maria Matilda Quigley

David Jose Simon Laine

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

Anti-PAR-2 antibodies and methods of use thereof

Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (K) of at least about 40 pM as determined by surface plasmon resonance.

Anti-IL-5 antibodies

Growing community of inventors

Haberfield, Australia

Mark Terence Liddament